Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osoresnontrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A known ✓ | O76083 | 20/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osoresnontrine SCHEMBL7885817 | 1.00 | PDE9A (1.00) | PDE9APDE1C | |
| SCHEMBL7882412 | 0.94 | PDE9A (0.89) | PDE9APDE1C | |
| SCHEMBL18635986 | 0.91 | PDE9A (0.84) | PDE9APDE1C | |
| SCHEMBL12401111 | 0.91 | PDE9A (0.83) | PDE9APDE1C | |
| SCHEMBL6343941 | 0.90 | PDE9A (0.82) | PDE9APDE1C | |
| SCHEMBL12401050 | 0.90 | PDE9A (0.81) | PDE9APDE1C | |
| SCHEMBL7993071 | 0.89 | PDE9A (0.79) | PDE9APDE1C | |
| SCHEMBL12465430 | 0.88 | PDE9A (0.78) | PDE9APDE1C | |
| SCHEMBL12400503 | 0.87 | PDE9A (0.77) | PDE9APDE1C | |
| SCHEMBL15417579 | 0.87 | PDE9A (0.77) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| EP-4659812-A1 | DETECTION METHODS AND COMBINATION THERAPIES OF CELLS WITH EXTRACELLULAR RAS EXPRESSION | Bumm, Thomas (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| CN-120093762-A | Phosphodiesterase 9A inhibitor for treating alcohol addiction and acute alcoholism | 南方医科大学 | 2025-06-06 | — | — | CN | disclosed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-119302958-A | Application of pharmaceutical preparation containing BAY 73-6691 or derivatives thereof in preparing medicine for treating brain injury diseases | 郑州大学第一附属医院 | 2025-01-14 | — | — | CN | disclosed |
| US-12144815-B2 | Use of aprepitant for treating Alzheimer's disease | HOTH THERAPEUTICS, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230374087-A1 | METHOD TO IMPROVE PROTEIN QUALITY CONTROL | THE JOHNS HOPKINS UNIVERSITY | 2023-11-23 | — | — | US | disclosed |
| CN-111410659-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20230128032-A1 | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death | CURTAILS LLC (US) | 2023-04-27 | — | — | US | disclosed |
| CN-111471059-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11434248-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| US-20220265672-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2022-08-25 | — | — | US | disclosed |
| WO-2022066899-A1 | METHOD TO IMPROVE PROTEIN QUALITY CONTROL | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220081409-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12144815-B2 | Use of aprepitant for treating Alzheimer's disease | TACR1, ACHE, TACR2 | PDE9A 2174/4885PDE1C 2066/4885 |
| US-20220265672-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | PDE9A 2174/4885PDE1C 2066/4885 |
| US-20220081409-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE9A, PDE5A, PDE12 | PDE9A 1/4885PDE1C 26/4885 |
| US-11434248-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | PDE9A 2/4885PDE1C 27/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | PDE9A 1/4885PDE1C 59/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | PDE9A 2174/4885PDE1C 2066/4885 |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE9A, PDE12, PDE5A | PDE9A 1/4885PDE1C 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.